GLP1R and type 2 diabetes mellitus: Given conflicting evidence for the effects of metformin and GLP‐1 receptor agonists, we utilized real‐world data to determine the individual and synergistic effects of both metformin and GLP‐1 RAs on the risk of adiposity‐related cancers in patients with T2D.